Urology Unit, Department of Neurosciences, Reproductive Sciences and Odontostomatology, University of Naples "Federico II", 80138 Naples, Italy.
Department of Urology, Humanitas Gavazzeni, 24125 Bergamo, Italy.
Medicina (Kaunas). 2024 Sep 5;60(9):1455. doi: 10.3390/medicina60091455.
: This study aimed to compare the effects and safety of boldine combined with and plus tamsulosin vs. tamsulosin alone in medical expulsive therapy (MET) for distal ureteral calculi. : This retrospective cohort study was conducted on 159 renal colic patients with distal ureteric stones (≤10 mm). Patients aged between 18 and 70 years or older with distal ureteral (below the sacroiliac joint) stones ≤10 mm (defined by the largest diameter in three planes) confirmed by urinary ultrasonography and/or native computed tomography (CT). Patients were divided into two groups: A and B. Patients in Group A received tamsulosin 0.4 mg plus boldine combined with and , while those in Group B received tamsulosin 0.4 mg. The rate of stone expulsion, duration of stone expulsion, the dose and the duration of nonsteroidal anti-inflammatory drugs (NSAIDs), analgesic use, and adverse effects of drugs were recorded. : No differences were reported in demographic profiles between the two groups. The stone expulsion rate in Group A (84.8%) was higher in comparison to Group B (52.5%); the mean time of stone expulsion was 16.33 ± 4.75 days in Group A and 19.33 ± 6.42 days in Group B. The mean requirement time of analgesia was significantly less in Group A, 2.42 ± 2.56, than in Group B, 6.25 ± 3.05. Drug-related adverse effects (headache, dizziness, nausea, vomiting, postural hypotension, backache, and running nose) were comparable between the two groups. : Tamsulosin plus boldine combined with and as medical expulsion therapy is more effective for distal ureteric stones with less need for analgesics and a shorter stone expulsion time than tamsulosin alone.
这项研究旨在比较与坦索罗辛单独治疗相比,博丁联合坦索罗辛和用于医学排石疗法(MET)治疗输尿管下段结石的效果和安全性。
这是一项回顾性队列研究,共纳入 159 例肾绞痛伴输尿管下段结石(≤10mm)患者。纳入标准为:年龄 18-70 岁或以上;经尿路超声和/或泌尿系 CT 确诊为输尿管下段结石(骶髂关节以下),结石大小≤10mm(定义为三个平面中最大直径);接受博丁联合坦索罗辛和用于 MET 治疗的患者纳入观察组(A 组),接受坦索罗辛 0.4mg 治疗的患者纳入对照组(B 组)。记录两组患者的结石排净率、排石时间、非甾体抗炎药(NSAIDs)用量和使用时间、止痛药用量和药物不良反应发生率。
两组患者的一般资料比较,差异无统计学意义。A 组结石排净率(84.8%)高于 B 组(52.5%),排石时间[(16.33±4.75)天]短于 B 组[(19.33±6.42)天],止痛药物使用时间[(2.42±2.56)天]短于 B 组[(6.25±3.05)天]。两组患者的药物不良反应(头痛、头晕、恶心、呕吐、体位性低血压、腰痛和流鼻涕)发生率比较,差异无统计学意义。
博丁联合坦索罗辛和用于 MET 治疗输尿管下段结石较坦索罗辛单独治疗更有效,排石时间更短,止痛药物使用时间更短。